UNSPSC 51111756: Ofatumumab

This classification denotes a monoclonal antibody with the molecular formula C6480H10022N1742O2020S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M95KG522R0, more generally known as ofatumumab. European Medicines Agency schedules ofatumumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25221. The term OFATUMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55.

OFATUMUMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Ofatumumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, OFATUMUMAB remains the US FDA Preferred Term for this commodity.. Ofatumumab bears US NLM identifiers UMLS ID C1832027 and NCI Concept Code C66952.

UNSPSC 51111756 Ofatumumab is a Commodity code for a specific monoclonal antibody pharmaceutical product. State and local governments procure ofatumumab primarily through piggyback and cooperative purchasing arrangements rather than direct purchase agreements, leveraging existing pharmaceutical warehouse and supply contracts negotiated at the state or regional level to manage inventory and ensure reliable access to this specialized therapeutic agent.

Activity under this code shows minimal recent direct solicitation, with no open RFPs, RFQs, or ITBs currently posted for ofatumumab itself. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (solicitation 26482DPHPREPDB53392, due September 11, 2026) for $2.99 million over 12 months with two renewal options; however, this contract covered doxycycline and ciprofloxacin rather than ofatumumab, reflecting the difficulty in matching specific pharmaceutical commodities to solicitation records. Seminole County, Florida posted an IFB on June 30, 2026 (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems through its e-Procurement Portal, also a non-match to the ofatumumab code. The absence of recent open solicitations specifically for ofatumumab suggests that state and local procurement of this product flows through established vendor relationships and standing cooperative contracts rather than competitive bid cycles; pursuit under this code should focus on securing inclusion in state pharmaceutical cooperative vehicles and regional health-system formularies rather than direct response to posted opportunities.